Submit Clinical Trial Notification for TransCon PTH in Japan
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- Q2 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plans to submit a Clinical Trial Notification for a clinical trial evaluating TransCon PTH for adult HP in Japan.”
What we found
Evidence strength A What the grades mean
The company confirmed in its 2022 20-F filing that it submitted the Clinical Trial Notification for the PaTHway Japan Trial during the second quarter of 2021.
-
A Ascendis Pharma A/S 20-F filed 2022-03-02
“In the second quarter of 2021, we submitted a Clinical Trial Notification (“CTN”) to the MHLW for PaTHway Japan Trial, a Phase 3 trial to evaluate the safety, tolerability, and efficacy of TransCon PTH.” ✓ confirmed on the page
Market reaction: the shares moved -4.5% against the S&P 500 over the three sessions around the disclosure (1 Mar 2022 to 4 Mar 2022). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- Clinical Trial Notification
- Where
- Japan
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Ascendis Pharma A/S? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ASND-021524 · Corrections policy